Salivary and serum carcinoembr yonic antigen (CEA) levels by two monoclonal immunoassays in normal controls (NC) and patients (PTS) with benign breast disease (BBD) and breast cancer (BCA): A novel approach

1987 ◽  
Vol 28 ◽  
pp. 29
Author(s):  
E.M. Gimenez-Q ◽  
M.L. Givner ◽  
B.J. Steele
Keyword(s):  
Breast Cancer ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Novel Approach ◽  
Normal Controls

scholarly journals Evaluation of serum PSA levels as a biomarker for breast carcinoma in north Indian females

2014 ◽  
Vol 5 (4) ◽  
pp. 25-28
Author(s):  
Nikhil Gupta ◽  
Binita Goswami ◽  
Shyamveer S Khangarot ◽  
Niladhar S Hadke
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Clinical Staging ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Normal Controls

Objective: Breast cancer has emerged as the most common malignancy among females during the last few years. Early diagnosis is essential for disease management so research is underway to identify potential serological bio markers with acceptable sensitivity and specificity. The current study was undertaken to compare the levels of serum PSA in patients with benign breast diseases, carcinoma breast and normal controls. Methods: The study was conducted jointly by the departments of Biochemistry and Surgery. Fifty patients of breast carcinoma were enrolled in the study, along with 50 cases of benign breast disease and 50 healthy controls. Serum PSA levels were estimated by Roche Elecsys modular Cobas e 411(electrochemiluminescence immuno assay) (Manheim Germany). Results: We did not find any significant differences in the PSA levels between normal controls, patients with benign breast disease as well as females presenting with breast carcinoma. No correlation was observed between serum PSA levels with clinical staging as well as histopathological grading. Conclusions: According to previous published studies, tumor levels of PSA are valuable for breast cancer patient prognosis, since patients with PSA positive tumors have much longer disease-free and overall survival. PSA levels in the serum of breast cancer patients are not significantly different from the PSA levels in the serum of normal women. Based on these data we conclude that serum PSA levels are not useful for breast cancer patient diagnosis or monitoring. DOI: http://dx.doi.org/10.3126/ajms.v5i4.7800 Asian Journal of Medical Sciences 2014 Vol.5(4); 25-28

scholarly journals Serum levels of oxidative stress marker malondialdehyde in breast cancer patients in relation to pathohistological factors, estrogen receptors, menopausal status, and age

2018 ◽  
Vol 8 (3) ◽  
pp. 154-161
Author(s):  
Jasmina Gubaljevic ◽  
Nahida Srabović ◽  
Adlija Jevrić-Čaušević ◽  
Adaleta Softić ◽  
Adi Rifatbegović ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Benign Breast Disease ◽  
Menopausal Status ◽  
Serum Levels ◽  
Breast Disease ◽  
Breast Cancer Patients ◽  
Node Metastases

Introduction: The aim of this study was to determine the serum levels of malondialdehyde (MDA) in patients with invasive breast cancer in relation to its serum levels in patients with benign breast disease, and to investigate correlation between MDA serum levels with pathohistological prognostic factors (tumor size, lymph node involvement, and histologic grade [HG]), estrogen receptor (ER) status, and with breast cancer patient’s age and menopausal status. Methods: A total of 43 with well-documented invasive breast cancer were included in this study: 27 with positive axillary’s lymph nodes, and 16 with negative axillary’s lymph nodes, and 39 patients with findings of benign breast diseases. MDA determination in serum of breast cancer and benign breast disease patients was performed by the fluorimetric method, immunohistochemical staining was performed for ER, and routine pathohistological examination was conducted for pathohistological factors. Results: MDA serum levels in breast cancer patients were significantly higher than MDA serum levels in benign breast disease patients (p = 0.042). No statistically significant difference between MDA serum levels in breast cancer patients with and without lymph node metastases was found (p = 0.238). No statistically significant correlations between MDA serum levels and tumor size (p = 0.256), HG (p = 0.124), or number of positive lymph nodes (0.113) were found. A statistically significant correlation between serum MDA levels and ages of breast cancer patients with lymph node metastases was found (p = 0.006). Conclusion: Obtained results support the importance of MDA in the carcinogenesis of breast cancer. According to our findings, serum level of MDA could not be a useful prognostic factor in breast cancer.

scholarly journals The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease

Cancer ◽  
2006 ◽  
Vol 107 (6) ◽  
pp. 1240-1247 ◽  
Author(s):  
Laura C. Collins ◽  
Heather J. Baer ◽  
Rulla M. Tamimi ◽  
James L. Connolly ◽  
Graham A. Colditz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Benign Breast Disease ◽  
Breast Disease
Sign in / Sign up

Export Citation Format

Share Document